Abstract
To evaluate the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. Prospective animal study. Laboratory. Twenty adult male Sprague Dawley rats were divided into 2 groups for hearing and tinnitus tests, respectively. The auditory brain-stem response (ABR) and the gap prepulse inhibition of acoustic startle (GPIAS) were used as indicators of hearing loss and tinnitus, respectively, and were measured before and at 2, 4, 6, 8, 12, 24, and 48 hours after administration of celecoxib (2 g/kg) via gavage. ABR threshold and wave III latencies did not increase significantly at any frequency following celecoxib administration, at any time point (P > .05). GPIAS remained below 30% after celecoxib, from a baseline of 20.03% ± 3.62%; no change was significant. High-dose celecoxib (2 g/kg), a selective COX-2 inhibitor, did not cause hearing loss or tinnitus in Sprague Dawley rats within 48 hours of administration. Further studies are needed to explore the roles played by COX-related mechanisms when nonselective COX inhibitors induce ototoxicity.
References
Jun 1, 1990·Hearing Research·P H Stypulkowski
Mar 1, 1995·Acta Oto-laryngologica·T T JungY S Park
Nov 18, 2005·Neuroscience Letters·Ulf-Rüdiger HeinrichWolf J Mann
Aug 15, 2006·Hearing Research·Guang YangWei Sun
Nov 7, 2006·International Journal of Pediatric Otorhinolaryngology·Jae-Gu ChoSung Won Chae
May 19, 2007·Allergy·M L KowalskiR Pawliczak
Aug 19, 2007·Behavior Research Methods·Franz FaulAxel Buchner
Aug 24, 2007·Audiology & Neuro-otology·Rosario Marchese-RagonaAlberto Staffieri
Nov 1, 2007·Journal of Basic and Clinical Physiology and Pharmacology·Uri PelegHaim Sohmer
Aug 30, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Louise S HarringtonJane A Mitchell
Nov 11, 2008·Biochemical and Biophysical Research Communications·Min Kyu ParkKi Churl Chang
Jan 22, 2009·Neuroscience·W SunR J Salvi
Jan 26, 2010·Neuroscience·A J NoreñaY Cazals
Mar 9, 2010·International Journal of Cardiology·Marie LordkipanidzéJean G Diodati
Oct 28, 2010·Clinical and Experimental Otorhinolaryngology·Gi Jung ImHak Hyun Jung
Jan 29, 2011·The Laryngoscope·Juen-Haur HwangYin-Ching Chan
Jun 16, 2011·PloS One·Min Dai, Xiaorui Shi
Jul 26, 2011·The Journal of Laryngology and Otology·I de Almeida-SilvaM A Hyppolito
Feb 7, 2012·Toxicology and Applied Pharmacology·Xianwei WangJawahar L Mehta
Oct 1, 2010·North American Journal of Medical Sciences·Ezekiel Uba Nwose, Nathan Cann
Dec 4, 2012·Hearing Research·Guang-Di ChenRichard Salvi
Feb 6, 2013·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Michael D SeidmanRobert T Standring
Mar 28, 2013·PloS One·Juen-Haur HwangYin-Ching Chan
May 18, 2013·British Journal of Cancer·T LiuD Xu
Aug 10, 2013·European Journal of Pain : EJP·M F CoronelS L González
Nov 19, 2013·PloS One·Zhiyuan WengWenquan Niu
Mar 8, 2014·World Journal of Gastrointestinal Pharmacology and Therapeutics·Carlos SostresAngel Lanas
Mar 22, 2014·International Journal of Oncology·Ning DingXi Zheng
Apr 8, 2014·European Journal of Histochemistry : EJH·S S HuH Wu
May 24, 2014·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·René H TolbaYuzo Yamamoto
Jun 11, 2014·Journal of Medical Economics·Nicholas BreretonRonald Akehurst
Aug 30, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Feng-Ying ZhangXiu-Li Shang
Sep 13, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Fan HeHui-Sheng Chen